Regenerative medicines

Developing and manufacturing cell-based regenerative therapeutics, from iPSC-derived CAR-T and CAR-NK cell therapies to iPSC-derived cardiomyocytes, neuronal progenitor & pancreatic beta cells (autologous/allogeneic) and engineered tissue and organ development using donor or patient-specific cells, is long, arduous path. We want to help.

The potential of regenerative medicines are undeniable.

However, numerous barriers - from complex tech transfers, batch-to-batch variability and six-figure dose production costs (just to name a few) stand between you and helping patients in need.

We want to help. Our ambition is to have Emmet be a single platform where you develop protocols (R&D), and then scale linearly through clinical trials and commercial production.

With Emmet you can:

Develop cell culture protocols on 'plug-and-play' cell culture vessel and fluid manifold cartridges;
Develop your CPQs and CMC strategey in parallel to your therapeutic discovery and development projects
Leverage in-line metabolic sensing systems to gain unprecedented control and insights into your early stage development (onboard imaging in development)
Develop a realistic manufacturing plan and cost of goods model from day one to meet your development and commercial goals.
...and beyond!

We are actively developing a GMP-compliant version of Emmet suitable for use in therapeutic manufacture for clinical trials - reach out to learn more.